This analysis focuses on the posthospital, secondary prevention of acute coronary syndrome (ACS), which typically involves the implementation of antithrombotic, neurohormonal blocking, and lipid-modifying strategies. The current ACS secondary prevention market is entrenched with generic therapies. Branded options include the oral antiplatelet agents Brilinta and Zontivity and the PCSK9 inhibitors Repatha and Praluent. Using a longitudinal claims data analysis, we demonstrate how secondary prevention of ACS is being treated in the United States and provide insights into what is driving current prescribing practices for newly diagnosed and recently treated patients.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ACS secondary prevention patients? What are the quarterly trends in prescribing?
- How has Brilinta been integrated into the treatment algorithm, and what is its source of business?
- What percentage of ACS secondary prevention patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ACS secondary prevention patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated ACS secondary prevention patients?
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Brilinta (ticagrelor), prasugrel, Zontivity, clopidogrel, Praluent, Repatha, ezetimibe, ACE inhibitors, ARBs, beta blockers, statins.
Key analysis provided: Brand/therapy usage across a longitudinal patient sample. Newly diagnosed patient analysis. Treatment initiation and progression. Line of therapy analysis. Combination therapy analysis. Source of business for recently treated patients. Persistency and compliance analysis. Product-level patient flowcharts.
Product description:Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis | Secondary Prevention (US)
- Treatment Algorithms US Claims Data Analysis | Acute Coronary Syndrome: Secondary Prevention | US | April 2019
Author(s): Conor Walsh
Conor Walsh, , is a Senior Director on the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources. Prior to joining Decision Resources, he worked at Medical Marketing Research International. Dr. Walsh holds an in bioinformatics and a in cardiac structural biology, both from the University of Manchester. For his doctoral work, he studied the molecular mechanisms underlying heart failure. Dr. Walsh earned his in biotechnology with first class honors from the National University of Ireland in Galway.